Next Generation Tissue Biomarkers Market Summary
The global next generation tissue biomarkers market size was valued at USD 3.3 billion in 2025 and is projected to grow from USD 3.6 billion in 2026 to USD 6.0 billion by 2033, at a CAGR of 7.5% from 2026 to 2033. North America dominated the market with the largest revenue share of 46.4% in 2025.
Global Next Generation Tissue Biomarkers Market Report Segmentation
This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global next generation tissue biomarkers market report based on product, application, technology, type, end use, and region:
- Product Outlook (Revenue, USD Million/Billion, 2021 - 2033)
- Reagents & Assays
- Instruments & Platforms
- Software & AI
- Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
- Genomic Biomarkers
- Proteomic Biomarkers
- Epigenetic Biomarkers
- Transcriptomic Biomarkers
- Metabolomic Biomarkers
- Technology Outlook (Revenue, USD Million/Billion, 2021 - 2033)
- Immunohistochemistry
- Next-Generation Sequencing (NGS)
- Mass Spectrometry (MS)-based Proteomics
- Spatial Biology Platforms
- Digital Pathology & AI Analysis
- Others
- Application Outlook (Revenue, USD Million/Billion, 2021 - 2033)
- Oncology
- Companion Diagnostics
- Drug Discovery & Development
- Neurology
- Others
- End-use Outlook (Revenue, USD Million/Billion, 2021 - 2033)
- Hospitals & Reference Labs
- Pharma & Biotech Companies
- Academic & Research Institutes
- Contract Research Organizations (CROs)
- Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
- North America
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
- UAE
- Kuwait